Exciting Developments in Spineart's BAGUERA®C Study
In a significant advancement for spine surgery innovation, Spineart has completed an interim analysis of its 1-level BAGUERA®C IDE study, which has met the necessary threshold for a non-inferiority claim. This promising finding represents a crucial milestone in the ongoing development of their innovative cervical disc prosthesis, which has the potential to change the landscape of cervical spine treatments.
Breakthrough in Regulatory Process
Spineart has now secured an agreement with the U.S. FDA regarding the timeline for the submission of Premarket Approval (PMA) for BAGUERA®C. This submission will be handled in three separate modules, allowing for a more structured review process. Notably, the completion of this PMA submission is expected by late 2025, which could lead to faster approval than initially anticipated, thereby accelerating patient access to this groundbreaking treatment.
Insights into the Clinical Study
The BAGUERA®C 1-level IDE trial is a carefully designed, prospective, multi-center randomized clinical study aimed at assessing the safety and effectiveness of BAGUERA®C. This prosthesis will be compared with the widely used Mobi-C® cervical disc for patients suffering from symptomatic cervical disease at a single level of the spine. The study enrolled a total of 285 patients across 25 different sites in the U.S., and the results from this clinical trial are pivotal for the forthcoming PMA submission to the FDA.
Leadership's Perspective
Jerome Trividic, the Chief Executive Officer of Spineart, shared his enthusiasm following the interim analysis. He stated, “This interim analysis data is extremely promising. We look forward to working with the FDA as we prepare to submit our PMA modules later this year, bringing us closer to making our innovative cervical disc prosthesis available to patients in the United States.” This indicates a solid commitment towards regulatory compliance and patient-centered innovation.
Understanding the BAGUERA®C Cervical Disc Prosthesis
The BAGUERA®C cervical disc prosthesis has been meticulously developed to preserve or restore motion and disc height in the cervical region after a single or two-level discectomy. Its design is aimed at maintaining the natural function of a spinal unit, enabling it to provide independent movement across six degrees of freedom, which includes various types of rotations and translational movements. This innovative approach could redefine how cervical disc diseases are treated, offering a versatile and adaptive solution for patients.
About Spineart: Pioneers in Spine Surgery
Spineart, known for its rapid growth in the spine surgery sector, is resolutely focused on enhancing the adoption of advanced technologies that benefit both surgeons and patients globally. Their mission underscores a dedication to Quality, Innovation, and Simplicity, which has propelled the company into the forefront of spinal surgery innovations. In recognition of their achievements, Spineart was awarded the "Prix de l'Economie Genevoise 2022" for its contributions to technological advancements and job creation.
Frequently Asked Questions
What is the purpose of the BAGUERA®C IDE study?
The BAGUERA®C IDE study aims to evaluate the safety and effectiveness of the BAGUERA®C cervical disc prosthesis compared to existing treatment options.
How many patients participated in the BAGUERA®C trial?
The trial enrolled 285 patients across 25 clinical sites in the U.S.
What did the interim analysis reveal?
The interim analysis confirmed that the BAGUERA®C met the threshold required for a non-inferiority claim, indicating its effectiveness compared to the control.
What is the planned timeline for FDA approval?
Spineart anticipates submitting the PMA for BAGUERA®C by late 2025, moving towards a faster approval process than initially expected.
How does the BAGUERA®C differ from conventional treatments?
The BAGUERA®C is designed to maintain the natural movement of the spine, providing increased functionality compared to traditional static solutions.
